Enovis (NYSE:ENOV) Releases Earnings Results, Beats Expectations By $0.06 EPS

Enovis (NYSE:ENOV) issued its earnings results on Wednesday. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.92 by $0.06, Zacks reports. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The firm had revenue of $560.98 million during the quarter, compared to analysts’ expectations of $555.14 million. Enovis updated its FY 2025 guidance to 3.100-3.250 EPS.

Enovis Price Performance

Shares of Enovis stock traded up $0.37 during midday trading on Friday, hitting $38.49. 482,432 shares of the company were exchanged, compared to its average volume of 968,302. The firm has a 50 day simple moving average of $44.81 and a 200-day simple moving average of $44.29. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The firm has a market cap of $2.19 billion, a P/E ratio of -17.56 and a beta of 1.94. Enovis has a 52 week low of $37.60 and a 52 week high of $63.96.

Analyst Ratings Changes

Separately, Needham & Company LLC reduced their price objective on shares of Enovis from $65.00 to $64.00 and set a “buy” rating for the company in a report on Thursday.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.